<p>北極星資產管理公司在最近向證券交易委員會的披露中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）的持股比例提高了 4.0%。該機構投資者在本季度增持了 12,271 股後，持有 316,783 股這家醫療產品製造商的股票。雅培約佔北極星資產管理公司持股的 1.6%，使其成為該公司第 11 大持股。北極星資產管理公司在雅培的持股在最近的報告期末價值為 39,690,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>AbbVie 發出健康趨勢跟隨信號：反彈即將到來嗎？</li>
</ul>
<p>其他對沖基金最近也增加或減少了對該公司的持股。Harbor Capital Advisors Inc.在第四季度新購入了價值約 27,000 美元的雅培股份。Cloud Capital Management LLC 在第三季度新購入了價值約 29,000 美元的雅培股份。Guerra Advisors Inc 在第三季度新購入了價值約 31,000 美元的雅培股份。Bridge Generations Wealth Management LLC 在第三季度新購入了價值約 33,000 美元的雅培股份。最後，Copia Wealth Management 在第三季度新購入了價值約 38,000 美元的雅培股份。機構投資者和對沖基金持有該公司 75.18% 的股票。</p>
<h2>雅培股票表現</h2>
<p>雅培股票在週五開盤價為 87.42 美元。該公司的 50 日簡單移動平均線為 96.74 美元，200 日簡單移動平均線為 112.05 美元。該股票的市值為 1522.7 億美元，市盈率為 24.49，PEG 比率為 1.46，貝塔值為 0.65。雅培的 12 個月低點為 81.97 美元，12 個月高點為 139.06 美元。該公司的債務與股本比率為 0.56，流動比率為 1.39，速動比率為 1.01。</p>
<ul>
<li>雅培股票崩盤：反彈可能即將到來</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近在 4 月 16 日（星期四）公佈了其財報。該醫療產品製造商報告本季度每股收益為 1.15 美元，超出分析師一致預期的 1.14 美元，超出幅度為 0.01 美元。該季度的營業收入為 111.6 億美元，而分析師預期為 109.9 億美元。雅培的淨利潤率為 13.90%，股本回報率為 17.62%。該公司的季度收入同比增長 7.8%。在去年同期，該公司每股收益為 1.09 美元。雅培已將其 2026 財年的指導目標設定為每股收益 5.380-5.580 美元，2026 年第二季度的指導目標設定為每股收益 1.250-1.310 美元。整體來看，股票分析師預測雅培在當前年度的每股收益將達到 5.48 美元。</p>
<h2>分析師評級升級與降級</h2>
<p>多位分析師對該股票發表了看法。大和證券集團將雅培的股票評級從 “跑贏大盤” 下調至 “中性”，並設定了 92.00 美元的目標價。在 4 月 22 日（星期三）的報告中，富國銀行將雅培的股票目標價從 122.00 美元下調至 109.00 美元，並給予 “增持” 評級。在 4 月 17 日（星期五）的報告中，花旗集團將雅培的股票目標價從 136.00 美元下調至 108.00 美元，並給予 “買入” 評級。Argus 在 4 月 21 日（星期二）的報告中將雅培的股票目標價從 140.00 美元下調至 125.00 美元，並給予 “買入” 評級。最後，派珀·桑德勒在 4 月 17 日（星期五）的報告中將雅培的股票目標價從 135.00 美元下調至 115.00 美元，並給予 “增持” 評級。有兩位研究分析師對該股票給予 “強烈買入” 評級，十九位分析師給予 “買入” 評級，五位分析師給予 “持有” 評級。根據 MarketBeat 的數據，雅培的共識評級為 “適度買入”，共識目標價為 119.43 美元。</p>
<ul>
<li>一家股息王正在打折出售：雅培是否是醫療保健的便宜貨？</li>
</ul>
<p><strong>查看我們最新的雅培股票報告</strong></p>
<h2>更多雅培新聞</h2>
<p>以下是本週影響雅培的主要新聞：</p>
<ul>
<li>積極情緒：TipRanks 的匯總顯示，雅培是三隻 “強烈買入” 股息貴族股票之一，具有超過 15% 的上漲潛力，這可能會增強投資者對該公司的信心。3 只 ‘強烈買入’ 股息貴族股票，15%+ 上漲潛力，2026 年 5 月 22 日</li>
<li>積極情緒：另一篇文章認為，雅培的 Lingo 可穿戴設備和增加的心血管研發可能通過擴大其健康科技和診斷領域來增強其長期增長前景。雅培的 Lingo 可穿戴設備和心血管研發重塑長期增長故事</li>
<li>中性情緒：一份市場報告稱，交易者在等待整合結果的更多明確性，暗示投資者處於 “展示我” 的階段，而不是完全重新定價該股票。等待整合結果，市場對雅培（ABT）保持温和</li>
<li>消極情緒：另一篇文章稱，雅培的股價部分下滑是因為其營養部門對消費者支出趨勢敏感，突顯了對關鍵業務線的宏觀壓力。雅培（ABT）因其營養部門對消費者支出動向的敏感性而下滑</li>
<li>消極情緒：高盛據報道將雅培從其美國信念名單中移除，這可能會對情緒產生影響，儘管這並未改變公司的基本面。儘管政策和成本壓力，為什麼聯合健康（UNH）仍然是一個翻身的賭注</li>
</ul>
<h2>內部人士下注</h2>
<p>在其他新聞中，執行副總裁 Daniel Gesua Sive Salvadori 於 3 月 2 日星期一出售了 885 股雅培（Abbott Laboratories）股票，交易的平均價格為 115.58 美元，總價值為 102,288.30 美元。交易後，這位執行副總裁直接持有公司 146,377 股股票，價值為 16,918,253.66 美元。此次交易使其持股減少了 0.60%。該出售在向 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，董事 Daniel J. Starks 於 4 月 27 日星期一購買了 10,000 股公司的股票，股票的平均購買成本為每股 92.65 美元，總交易額為 926,500.00 美元。完成購買後，該董事直接持有公司 6,751,103 股股票，價值為 625,489,692.95 美元。此次交易使其持股增加了 0.15%。該購買的披露信息可在 SEC 文件中找到。在過去的九十天裏，內部人士出售了 3,055 股公司股票，價值為 353,097 美元。公司內部人士持有 0.46% 的公司股票。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培（Abbott Laboratories）是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷領域，雅培提供實驗室和現場檢測平台及檢測方法，用於檢測傳染病、慢性病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>Workday 驗證 AI 飛輪：股票價格恢復開始</li>
<li>HubSpot 在 2019 年水平是一個機會——而不是警告</li>
<li>Decker 的雙重超預期是看漲信號——還是僅僅是 HOKA 的把戲？</li>
<li>Kiniksa Pharmaceuticals 在 100% 反彈後仍有上漲空間</li>
</ul>
<p><strong>想看看其他對 ABT 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

標普健康醫療設備 ETF - SPDR

基因改革 ETF - ARK

標普全球醫療股指數 ETF - iShares

醫療業 ETF - Vanguard

醫療業 ETF - SPDR

美國制藥 ETF - iShares

美國醫藥設備 ETF - iShares

<p>北星資產管理公司在第四季度將其在雅培（NYSE:ABT）的持股增加了 4.0%，目前持有 316,783 股，市值為 3969 萬美元。該公司現在是北星的第 11 大持股。其他對沖基金也增持了雅培的股份。該股票開盤價為 87.42 美元，市值為 1522.7 億美元。分析師的評級意見不一，普遍評級為 “適度買入”，目標價為 119.43 美元</p>

<p>North Star Asset Management Inc. boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 316,783 shares of the healthcare product maker's stock after acquiring an additional 12,271 shares during the quarter. Abbott Laboratories accounts for about 1.6% of North Star Asset Management Inc.'s holdings, making the stock its 11th biggest holding. North Star Asset Management Inc.'s holdings in Abbott Laboratories were worth $39,690,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>北極星資產管理公司在最近向證券交易委員會的披露中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）的持股比例提高了 4.0%。該機構投資者在本季度增持了 12,271 股後，持有 316,783 股這家醫療產品製造商的股票。雅培約佔北極星資產管理公司持股的 1.6%，使其成為該公司第 11 大持股。北極星資產管理公司在雅培的持股在最近的報告期末價值為 39,690,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 發出健康趨勢跟隨信號：反彈即將到來嗎？</li>
</ul>
</div><p>Other hedge funds have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories during the third quarter worth approximately $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the third quarter worth approximately $38,000. Institutional investors and hedge funds own 75.18% of the company's stock.</p>
<div class="lb-trans"><p>其他對沖基金最近也增加或減少了對該公司的持股。Harbor Capital Advisors Inc.在第四季度新購入了價值約 27,000 美元的雅培股份。Cloud Capital Management LLC 在第三季度新購入了價值約 29,000 美元的雅培股份。Guerra Advisors Inc 在第三季度新購入了價值約 31,000 美元的雅培股份。Bridge Generations Wealth Management LLC 在第三季度新購入了價值約 33,000 美元的雅培股份。最後，Copia Wealth Management 在第三季度新購入了價值約 38,000 美元的雅培股份。機構投資者和對沖基金持有該公司 75.18% 的股票。</p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><p>Shares of Abbott Laboratories stock opened at $87.42 on Friday. The firm's fifty day simple moving average is $96.74 and its 200-day simple moving average is $112.05. The stock has a market capitalization of $152.27 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.</p>
<div class="lb-trans"><p>雅培股票在週五開盤價為 87.42 美元。該公司的 50 日簡單移動平均線為 96.74 美元，200 日簡單移動平均線為 112.05 美元。該股票的市值為 1522.7 億美元，市盈率為 24.49，PEG 比率為 1.46，貝塔值為 0.65。雅培的 12 個月低點為 81.97 美元，12 個月高點為 139.06 美元。該公司的債務與股本比率為 0.56，流動比率為 1.39，速動比率為 1.01。</p>
</div><ul>
<li>Abbott Stock Crash: Rebound Could Be Coming Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培股票崩盤：反彈可能即將到來</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近在 4 月 16 日（星期四）公佈了其財報。該醫療產品製造商報告本季度每股收益為 1.15 美元，超出分析師一致預期的 1.14 美元，超出幅度為 0.01 美元。該季度的營業收入為 111.6 億美元，而分析師預期為 109.9 億美元。雅培的淨利潤率為 13.90%，股本回報率為 17.62%。該公司的季度收入同比增長 7.8%。在去年同期，該公司每股收益為 1.09 美元。雅培已將其 2026 財年的指導目標設定為每股收益 5.380-5.580 美元，2026 年第二季度的指導目標設定為每股收益 1.250-1.310 美元。整體來看，股票分析師預測雅培在當前年度的每股收益將達到 5.48 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>A number of analysts have weighed in on the stock. Daiwa Securities Group cut shares of Abbott Laboratories from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Wells Fargo &amp; Company cut their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Citigroup cut their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, April 17th. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, April 21st. Finally, Piper Sandler cut their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $119.43.</p>
<div class="lb-trans"><p>多位分析師對該股票發表了看法。大和證券集團將雅培的股票評級從 “跑贏大盤” 下調至 “中性”，並設定了 92.00 美元的目標價。在 4 月 22 日（星期三）的報告中，富國銀行將雅培的股票目標價從 122.00 美元下調至 109.00 美元，並給予 “增持” 評級。在 4 月 17 日（星期五）的報告中，花旗集團將雅培的股票目標價從 136.00 美元下調至 108.00 美元，並給予 “買入” 評級。Argus 在 4 月 21 日（星期二）的報告中將雅培的股票目標價從 140.00 美元下調至 125.00 美元，並給予 “買入” 評級。最後，派珀·桑德勒在 4 月 17 日（星期五）的報告中將雅培的股票目標價從 135.00 美元下調至 115.00 美元，並給予 “增持” 評級。有兩位研究分析師對該股票給予 “強烈買入” 評級，十九位分析師給予 “買入” 評級，五位分析師給予 “持有” 評級。根據 MarketBeat 的數據，雅培的共識評級為 “適度買入”，共識目標價為 119.43 美元。</p>
</div><ul>
<li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li>
</ul>
<div class="lb-trans"><ul>
<li>一家股息王正在打折出售：雅培是否是醫療保健的便宜貨？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on ABT</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的雅培股票報告</strong></p>
</div><h2>More Abbott Laboratories News</h2>
<div class="lb-trans"><h2>更多雅培新聞</h2>
</div><p>Here are the key news stories impacting Abbott Laboratories this week:</p>
<div class="lb-trans"><p>以下是本週影響雅培的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26</li>
<li>Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&amp;D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&amp;D Reframe Long Term Growth Story</li>
<li>Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)</li>
<li>Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum</li>
<li>Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：TipRanks 的匯總顯示，雅培是三隻 “強烈買入” 股息貴族股票之一，具有超過 15% 的上漲潛力，這可能會增強投資者對該公司的信心。3 只 ‘強烈買入’ 股息貴族股票，15%+ 上漲潛力，2026 年 5 月 22 日</li>
<li>積極情緒：另一篇文章認為，雅培的 Lingo 可穿戴設備和增加的心血管研發可能通過擴大其健康科技和診斷領域來增強其長期增長前景。雅培的 Lingo 可穿戴設備和心血管研發重塑長期增長故事</li>
<li>中性情緒：一份市場報告稱，交易者在等待整合結果的更多明確性，暗示投資者處於 “展示我” 的階段，而不是完全重新定價該股票。等待整合結果，市場對雅培（ABT）保持温和</li>
<li>消極情緒：另一篇文章稱，雅培的股價部分下滑是因為其營養部門對消費者支出趨勢敏感，突顯了對關鍵業務線的宏觀壓力。雅培（ABT）因其營養部門對消費者支出動向的敏感性而下滑</li>
<li>消極情緒：高盛據報道將雅培從其美國信念名單中移除，這可能會對情緒產生影響，儘管這並未改變公司的基本面。儘管政策和成本壓力，為什麼聯合健康（UNH）仍然是一個翻身的賭注</li>
</ul>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company's stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Daniel Gesua Sive Salvadori 於 3 月 2 日星期一出售了 885 股雅培（Abbott Laboratories）股票，交易的平均價格為 115.58 美元，總價值為 102,288.30 美元。交易後，這位執行副總裁直接持有公司 146,377 股股票，價值為 16,918,253.66 美元。此次交易使其持股減少了 0.60%。該出售在向 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，董事 Daniel J. Starks 於 4 月 27 日星期一購買了 10,000 股公司的股票，股票的平均購買成本為每股 92.65 美元，總交易額為 926,500.00 美元。完成購買後，該董事直接持有公司 6,751,103 股股票，價值為 625,489,692.95 美元。此次交易使其持股增加了 0.15%。該購買的披露信息可在 SEC 文件中找到。在過去的九十天裏，內部人士出售了 3,055 股公司股票，價值為 353,097 美元。公司內部人士持有 0.46% 的公司股票。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories）是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷領域，雅培提供實驗室和現場檢測平台及檢測方法，用於檢測傳染病、慢性病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Workday Validates AI Flywheel: Stock Price Recovery Begins</li>
<li>HubSpot at 2019 Levels Is an Opportunity—Not a Warning</li>
<li>Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?</li>
<li>Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>Workday 驗證 AI 飛輪：股票價格恢復開始</li>
<li>HubSpot 在 2019 年水平是一個機會——而不是警告</li>
<li>Decker 的雙重超預期是看漲信號——還是僅僅是 HOKA 的把戲？</li>
<li>Kiniksa Pharmaceuticals 在 100% 反彈後仍有上漲空間</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 ABT 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Abbott Laboratories $ABT Shares Purchased by North Star Asset Management Inc.

Market Beat

艾伯維

Daiwa Securities Group Inc.

富國銀行

花旗

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

CITIGROUP INC 6.250 NON CUM SER II PFD WI

北極星資產管理公司購買了雅培公司 $ABT 的股票